The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
CTLA-4: From mechanism to autoimmune therapy
Abstract
CD28 and CTLA-4 are both important stimulatory receptors for the regulation of T cell activation. Because receptors share common ligands, B7.1 and B7.2, the expression and biological function of CTLA-4 is important for the negative regulation of T cell responses. Therefore, elimination of CTLA-4 can result in the breakdown of immune tolerance and the development of several diseases such as autoimmunity. Inhibitory signals of CTLA-4 suppress T cell responses and protect against autoimmune diseases in many ways. In this review, we summarize the structure, expression and signaling pathway of CTLA-4. We also highlight how CTLA-4 defends against potentially self-reactive T cells. Finally, we discuss how the CTLA-4 regulates a number of autoimmune diseases that indicate manipulation of this inhibitory molecule is a promise as a strategy for the immunotherapy of autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 1,993
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Zhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R. P., & Samelson, L. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80901-0 · Cited by 1,267
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
New insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.042 · Cited by 1,189
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G., & Thompson, C. B. (1989) · Science · doi:10.1126/science.2540528 · Cited by 878
Defective Suppressor Function in CD4+CD25+ T-Cells From Patients With Type 1 Diabetes
Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peakman, M., & Tree, T. I. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.92 · Cited by 861
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835
Prakken, B., Albani, S., & Martini, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60244-4 · Cited by 771
Ohkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y., Osaki, M., Tanaka, Y., Yamashita, R., Nakano, N., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.010 · Cited by 754
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Molecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
Multiple immuno-regulatory defects in type-1 diabetes
Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin‐Su, K., Ten, S., Sanz, M. M., Exley, M. A., Wilson, B., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13605 · Cited by 640
T cell receptor ligation induces the formation of dynamically regulated signaling assemblies
Bunnell, S. C., Hong, D. I., Kardon, J. R., Yamazaki, T., McGlade, C. J., Barr, V. A., & Samelson, L. E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203043 · Cited by 632
Reversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621
Powrie, F., Correa-Oliveira, R., Mauze, S., & Coffman, R. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.589 · Cited by 613
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR Engagement
Linsley, P. S., Bradshaw, J., Greene, J., Peach, R., Bennett, K. L., & Mittler, R. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80480-x · Cited by 609
One year in review 2020: pathogenesis of rheumatoid arthritis
Giannini, D., Antonucci, M., Petrelli, F., Bilia, S., Alunno, A., & Puxeddu, I. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/3uj1ng · Cited by 588
Multiple immuno-regulatory defects in type-1 diabetes
Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin-Su, K., Ten, S., Sanz, M., Exley, M., Wilson, B., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213605 · Cited by 566
Ruperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C. A., Abud-Mendoza, C., Burgos-Vargas, R., Gerloni, V., Melo-Gomes, J. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60998-8 · Cited by 560
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Simon, T. A., Thompson, A., Gandhi, K. K., Hochberg, M. C., & Suissa, S. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0728-9 · Cited by 557
Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4
Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., Saldate, C., Li, T., Aranda, R., Becker, J.-C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080002 · Cited by 539
Egen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 535
van Amelsfort, J. M. R., Jacobs, K. M. G., Bijlsma, J. W. J., Lafeber, F. P. J. G., & Taams, L. S. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20499 · Cited by 531
Kouki, T., Sawai, Y., Gardine, C. A., Fisfalen, M.-E., Alegre, M.-L., & DeGroot, L. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6606 · Cited by 505
MOLKENTIN, J. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.01.021 · Cited by 497
LAT Is Required for TCR-Mediated Activation of PLCγ1 and the Ras Pathway
Finco, T. S., Kadlecek, T., Zhang, W., Samelson, L. E., & Weiss, A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80659-7 · Cited by 495
Izcue, A., Coombes, J. L., & Powrie, F. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00423.x · Cited by 474
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature Reviews Immunology · doi:10.1038/nri2163 · Cited by 453
Sage, P. T., Paterson, A. M., Lovitch, S. B., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.005 · Cited by 437
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
CTLA-4 in autoimmune diseases – a general susceptibility gene to autoimmunity?
Kristiansen, O., Larsen, Z., & Pociot, F. (2000) · Genes & Immunity · doi:10.1038/sj.gene.6363655 · Cited by 414
Marron, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1275 · Cited by 407
CTLA4 Alanine-17 Confers Genetic Susceptibility to Graves’ Disease and to Type 1 Diabetes Mellitus1
Donner, H., Rau, H., Walfish, P. G., Braun, J., Siegmund, T., Finke, R., Herwig, J., Usadel, K. H., & Badenhoop, K. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3699 · Cited by 396
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392
Wing, J. B., Ise, W., Kurosaki, T., & Sakaguchi, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.006 · Cited by 388
Effective treatment of collagen‐induced arthritis by adoptive transfer of CD25+ regulatory T cells
Morgan, M. E., Flierman, R., van Duivenvoorde, L. M., Witteveen, H. J., van Ewijk, W., van Laar, J. M., de vries, R. R. P., & Toes, R. E. M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21195 · Cited by 385
Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis
Mohan, C., & Putterman, C. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.33 · Cited by 377
Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function
Tang, Q., Boden, E. K., Henriksen, K. J., Bour‐Jordan, H., Bi, M., & Bluestone, J. A. (2004) · European Journal of Immunology · doi:10.1002/eji.200425143 · Cited by 377
Merrill, J. T., Burgos‐Vargas, R., Westhovens, R., Chalmers, A., D'Cruz, D., Wallace, D. J., Bae, S. C., Sigal, L., Becker, J. ‐., Kelly, S., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27601 · Cited by 376
CTLA-4: a negative regulator of autoimmune disease.
Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.783 · Cited by 376
Confusing signals: Recent progress in CTLA-4 biology
Walker, L. S. K., & Sansom, D. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.001 · Cited by 361
Genetics of type 1 diabetes mellitus
Pociot, F., & McDermott, M. F. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363875 · Cited by 359
Type 1 diabetes associated autoimmunity: natural history, genetic associations and screening
Barker, J. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1679 · Cited by 350
Westhovens, R., Robles, M., Ximenes, A. C., Nayiager, S., Wollenhaupt, J., Durez, P., Gomez-Reino, J., Grassi, W., Haraoui, B., Shergy, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101121 · Cited by 348
Shiratori, T., Miyatake, S., Ohno, H., Nakaseko, C., Isono, K., Bonifacino, J. S., & Saito, T. (1997) · Immunity · doi:10.1016/s1074-7613(00)80346-5 · Cited by 345
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., Bourdier de Beauregard, M., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv227 · Cited by 340
Regulation of surface and intracellular expression of CTLA4 on mouse T cells
Alegre, M. L., Noel, P. J., Eisfelder, B. J., Chuang, E., Clark, M. R., Reiner, S. L., & Thompson, C. B. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4762 · Cited by 338
Liu, S. K., Fang, N., Koretzky, G. A., & Jane McGlade, C. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80017-7 · Cited by 329
Sonkoly, E., Janson, P., Majuri, M.-L., Savinko, T., Fyhrquist, N., Eidsmo, L., Xu, N., Meisgen, F., Wei, T., Bradley, M., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.045 · Cited by 317
One year in review 2021: pathogenesis of rheumatoid arthritis
Testa, D., Calvacchi, S., Petrelli, F., Giannini, D., Bilia, S., Alunno, A., & Puxeddu, I. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/j1l5l3 · Cited by 314
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis
Flores-Borja, F., Jury, E. C., Mauri, C., & Ehrenstein, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806855105 · Cited by 312
CD25+ cell depletion hastens the onset of severe disease in collagen‐induced arthritis
Morgan, M. E., Sutmuller, R. P. M., Witteveen, H. J., van Duivenvoorde, L. M., Zanelli, E., Melief, C. J. M., Snijders, A., Offringa, R., de Vries, R. R. P., & Toes, R. E. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11063 · Cited by 305
The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A
Chuang, E., Fisher, T. S., Morgan, R. W., Robbins, M. D., Duerr, J. M., Vander Heiden, M. G., Gardner, J. P., Hambor, J. E., Neveu, M. J., & Thompson, C. B. (2000) · Immunity · doi:10.1016/s1074-7613(00)00031-5 · Cited by 303
Yamasaki, K., Kira, J., Kawano, Y., Kobayashi, T., Kanai, T., Nishimura, Y., Matsushita, S., Hasuo, K., & Tobimatsu, S. (1996) · Annals of Neurology · doi:10.1002/ana.410400405 · Cited by 302
Dariavach, P., Mattéi, M., Golstein, P., & Lefranc, M. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181206 · Cited by 301
Prasad, K. V., Cai, Y. C., Raab, M., Duckworth, B., Cantley, L., Shoelson, S. E., & Rudd, C. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2834 · Cited by 295
Schiff, M., Weinblatt, M. E., Valente, R., van der Heijde, D., Citera, G., Elegbe, A., Maldonado, M., & Fleischmann, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203843 · Cited by 293
CTLA4 Alanine-17 Confers Genetic Susceptibility to Graves' Disease and to Type 1 Diabetes Mellitus
Donner, H. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.1.143 · Cited by 284
Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3370 · Cited by 277
Magistrelli, G., Jeannin, P., Herbault, N., Benoit de Coignac, A., Gauchat, J.-F., Bonnefoy, J.-Y., & Delneste, Y. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3596::aid-immu3596>3.0.co;2-y · Cited by 276
Systematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
CD4 T-cell differentiation and inflammatory bowel disease
Zenewicz, L. A., Antov, A., & Flavell, R. A. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.03.002 · Cited by 266
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., Li, T., Schmidely, N., Le Bars, M., & Dougados, M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074773 · Cited by 264
Lovett-Racke, A. E., Trotter, J. L., Lauber, J., Perrin, P. J., June, C. H., & Racke, M. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1528 · Cited by 260
Jain, N., Nguyen, H., Chambers, C., & Kang, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910341107 · Cited by 256
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
de Mattos, B. R. R., Garcia, M. P. G., Nogueira, J. B., Paiatto, L. N., Albuquerque, C. G., Souza, C. L., Fernandes, L. G. R., Tamashiro, W. M. D. S. C., & Simioni, P. U. (2015) · Mediators of Inflammation · doi:10.1155/2015/493012 · Cited by 251
Weinblatt, M. E., Schiff, M., Valente, R., van der Heijde, D., Citera, G., Zhao, C., Maldonado, M., & Fleischmann, R. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37711 · Cited by 250
Structure and Dimerization of a Soluble Form of B7-1
Ikemizu, S., Gilbert, R. J. C., Fennelly, J. A., Collins, A. V., Harlos, K., Jones, E. Y., Stuart, D. I., & Davis, S. J. (2000) · Immunity · doi:10.1016/s1074-7613(00)80158-2 · Cited by 249
CD4+CD28– costimulation-independent T cells in multiple sclerosis
Markovic‐Plese, S., Cortese, I. C. M., Wandinger, K., McFarland, H. F., & Martinꝉ, R. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12516 · Cited by 243
Emery, P. E., Burmester, G. R., Bykerk, V. P., Combe, B. G., Fürst, D. E., Barré, E., Karyekar, C. S., Wong, D. A., & Huizinga, T. W. J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206106 · Cited by 241
Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease
Oaks, M. K., & Hallett, K. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5015 · Cited by 239
Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment
Vivino, F. B., Bunya, V. Y., Massaro-Giordano, G., Johr, C. R., Giattino, S. L., Schorpion, A., Shafer, B., Peck, A., Sivils, K., Rasmussen, A., et al. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.04.009 · Cited by 238
Cutting Edge: Lymphoproliferative Disease in the Absence of CTLA-4 Is Not T Cell Autonomous
Bachmann, M. F., Köhler, G., Ecabert, B., Mak, T. W., & Kopf, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1128 · Cited by 235
Meiners, P. M., Vissink, A., Kroese, F. G. M., Spijkervet, F. K. L., Smitt-Kamminga, N. S., Abdulahad, W. H., Bulthuis-Kuiper, J., Brouwer, E., Arends, S., & Bootsma, H. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204653 · Cited by 233
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Vijayakrishnan, L., Slavik, J. M., Illés, Z., Greenwald, R. J., Rainbow, D., Greve, B., Peterson, L. B., Hafler, D. A., Freeman, G. J., Sharpe, A. H., et al. (2004) · Immunity · doi:10.1016/s1074-7613(04)00110-4 · Cited by 218
Yokosuka, T., Kobayashi, W., Takamatsu, M., Sakata-Sogawa, K., Zeng, H., Hashimoto-Tane, A., Yagita, H., Tokunaga, M., & Saito, T. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.006 · Cited by 213
Abatacept treatment for rheumatoid arthritis
Schiff, M. (2010) · Rheumatology · doi:10.1093/rheumatology/keq287 · Cited by 210
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2014) · Diabetes Care · doi:10.2337/dc13-0604 · Cited by 209
CTLA-4 directly inhibits osteoclast formation
Axmann, R., Herman, S., Zaiss, M., Franz, S., Polzer, K., Zwerina, J., Herrmann, M., Smolen, J., & Schett, G. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080713 · Cited by 200
Abatacept: A Review in Rheumatoid Arthritis
Blair, H. A., & Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0775-4 · Cited by 199
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
Sloka, J. S., & Stefanelli, M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1190oa · Cited by 195
Leung, H. T., Bradshaw, J., Cleaveland, J. S., & Linsley, P. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.25107 · Cited by 191
CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
Chikuma, S. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_61 · Cited by 187
Venken, K., Hellings, N., Hensen, K., Rummens, J., Medaer, R., D'hooghe, M. B., Dubois, B., Raus, J., & Stinissen, P. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20852 · Cited by 185
Brode, S., Raine, T., Zaccone, P., & Cooke, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6603 · Cited by 185
Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein
Zhang, Y., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9273 · Cited by 181
Wang, C. J., Heuts, F., Ovcinnikovs, V., Wardzinski, L., Bowers, C., Schmidt, E. M., Kogimtzis, A., Kenefeck, R., Sansom, D. M., & Walker, L. S. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414576112 · Cited by 179
Truitt, K. E., Hicks, C. M., & Imboden, J. B. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1071 · Cited by 179
Schmidt, E. M., Wang, C. J., Ryan, G. A., Clough, L. E., Qureshi, O., Goodall, M. D., Abbas, A. K., Sharpe, A. H., Sansom, D. M., & Walker, L. S. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.274 · Cited by 176
Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M., & Cerwenka, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302091 · Cited by 175
Iida, T., Ohno, H., Nakaseko, C., Sakuma, M., Takeda-Ezaki, M., Arase, H., Kominami, E., Fujisawa, T., & Saito, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5062 · Cited by 173
Kavvoura, F. K., & Ioannidis, J. P. A. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi165 · Cited by 173
Schneider, H., Martín, M., Agarraberes, F. A., Yin, L., Rapoport, I., Kirchhausen, T. L., & Rudd, C. E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1868 · Cited by 171
Verstappen, G. M., Meiners, P. M., Corneth, O. B. J., Visser, A., Arends, S., Abdulahad, W. H., Hendriks, R. W., Vissink, A., Kroese, F. G. M., & Bootsma, H. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40165 · Cited by 170
Multiple Sclerosis and Regulatory T Cells
Costantino, C. M., Baecher-Allan, C., & Hafler, D. A. (2008) · Journal of Clinical Immunology · doi:10.1007/s10875-008-9236-x · Cited by 165
CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells.
Schneider, H., Prasad, K. V., Shoelson, S. E., & Rudd, C. E. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.351 · Cited by 165
Structure of Murine CTLA-4 and Its Role in Modulating T Cell Responsiveness
Ostrov, D. A., Shi, W., Schwartz, J.-C. D., Almo, S. C., & Nathenson, S. G. (2000) · Science · doi:10.1126/science.290.5492.816 · Cited by 164
T cell antigen receptor activation and actin cytoskeleton remodeling
Kumari, S., Curado, S., Mayya, V., & Dustin, M. L. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.05.004 · Cited by 164
Cross, A. H., Girard, T. J., Giacoletto, K. S., Evans, R. J., Keeling, R. M., Lin, R. F., Trotter, J. L., & Karr, R. W. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117982 · Cited by 162
The clinical utility of inhibiting CD28‐mediated costimulation
Linsley, P. S., & Nadler, S. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00780.x · Cited by 162
Cribbs, A. P., Kennedy, A., Penn, H., Read, J. E., Amjadi, P., Green, P., Syed, K., Manka, S. W., Brennan, F. M., Gregory, B., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38715 · Cited by 158
Schiff, M. H., Pritchard, C., Huffstutter, J. E., Rodrı́guez-Valverde, V., Durez, P., Zhou, X., Li, T., Bahrt, K., Kelly, S., Bars, M. L., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099218 · Cited by 156
Martín, M., Schneider, H., Azouz, A., & Rudd, C. E. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.11.1675 · Cited by 156
Gross, J. A., John, T. S., & Allison, J. P. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.8.3201 · Cited by 154
B-cell hyperactivity in primary Sjögren's syndrome
Kroese, F. G. M., Abdulahad, W. H., Haacke, E. A., Bos, N. A., Vissink, A., & Bootsma, H. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.891439 · Cited by 153
Buch, M. H., Boyle, D. L., Rosengren, S., Saleem, B., Reece, R. J., Rhodes, L. A., Radjenovic, A., English, A., Tang, H., Vratsanos, G., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091876 · Cited by 153
The CTLA-4 gene is associated with multiple sclerosis
Ligers, A., Xu, C., Saarinen, S., Hillert, J. A., & Olerup, O. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00072-7 · Cited by 150
Stein, P. H., Fraser, J. D., & Weiss, A. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.5.3392 · Cited by 150
Salojin, K. V., Zhang, J., & Delovitch, T. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.844 · Cited by 148
Protein kinase C-η controls CTLA-4–mediated regulatory T cell function
Kong, K., Fu, G., Zhang, Y., Yokosuka, T., Casas, J., Canonigo-Balancio, A. J., Bécart, S., Kim, G., Yates, J. R., Kronenberg, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2866 · Cited by 147
Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4
Zeißig, S., Petersen, B., Tomczak, M. F., Melum, E., Huc‐Claustre, E., Dougan, S. K., Laerdahl, J. K., Stade, B., Förster, M., Schreiber, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-308541 · Cited by 146
Awata, T., Kurihara, S., Iitaka, M., et al. (1998) · Diabetes · doi:10.2337/diab.47.1.128 · Cited by 144
Abatacept for Crohn's Disease and Ulcerative Colitis
Sandborn, W. J., Colombel, J., Sands, B. E., Rutgeerts, P. J., Targan, S. R., Panaccione, R., Bressler, B. L., Geboes, K., Schreiber, S., Aranda, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.010 · Cited by 142
Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135
Schneider, H., Martı́n, M., Agarraberes, F. A., Yin, L., Rapoport, I., Kirchhausen, T. L., & Rudd, C. E. (1999) · PubMed · Cited by 134
CTLA-4 regulates cell cycle progression during a primary immune response
Greenwald, R. J., Oosterwegel, M. A., van der Woude, D., Kubal, A., Mandelbrot, D. A., Boussiotis, V. A., & Sharpe, A. H. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200202)32:2<366::aid-immu366>3.0.co;2-5 · Cited by 133
Adler, S., Körner, M., Förger, F., Huscher, D., Caversaccio, M., & Villiger, P. M. (2013) · Arthritis Care & Research · doi:10.1002/acr.22052 · Cited by 130
Chambers, C. A., Kuhns, M. S., & Allison, J. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8603 · Cited by 129
Simon, T. A., Smitten, A. L., Franklin, J. P., Askling, J., Lacaille, D. V., Wolfe, F., Hochberg, M. C., Qi, K., & Suissa, S. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.097527 · Cited by 129
Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter
Gibson, H. M., Hedgcock, C. J., Aufiero, B. M., Wilson, A. J., Hafner, M. S., Tsokos, G. C., & Wong, H. K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3831 · Cited by 126
Gottenberg, J., Courvoisier, D. S., Hernández, M. V., Iannone, F., Lie, E., Canhão, H. M., Pavelká, K., Hetland, M. L., Turesson, C., Xavier Mariette, A., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39595 · Cited by 123
CD8+CD28− Regulatory T Lymphocytes Prevent Experimental Inflammatory Bowel Disease in Mice
Marcq, I., Pomié, C., Romagnoli, P., & van Meerwijk, J. P. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.008 · Cited by 122
Lim, S., Kim, W., Kim, Y.-H., Lee, S., Koo, J., Lee, J.-A., Yoon, H., Kim, D.-H., Park, H.-J., Kim, H.-M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9244 · Cited by 122
CTLA4 ligation attenuates AP-1, NFAT and NF-κB activity in activated T cells
Fraser, J., Rincón, M., McCoy, K. D., & Gros, G. S. L. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199903)29:03<838::aid-immu838>3.0.co;2-p · Cited by 120
Cutting Edge: CTLA-4–B7 Interaction Suppresses Th17 Cell Differentiation
Ying, H., Yang, L., Qiao, G., Li, Z., Zhang, L., Yin, F., Xie, D., & Zhang, J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903369 · Cited by 118
Schneider, H., Smith, X., Liu, H., Bismuth, G., & Rudd, C. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737423 · Cited by 116
Liu, Z., Geboes, K. J., Hellings, P. W., Maerten, P., Heremans, H., Vandenberghe, P., Boon, L., van Kooten, P. J. S., Rutgeerts, P. J., & Ceuppens, J. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1830 · Cited by 116
Kalia, V., Penny, L. A., Yuzefpolskiy, Y., Baumann, F. M., & Sarkar, S. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.023 · Cited by 113
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
Corse, E., & Allison, J. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200695 · Cited by 111
Tai, X., Laethem, F. V., Sharpe, A. H., & Singer, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706509104 · Cited by 109
Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population
Lei, C., Dongqing, Z., Yeqing, S., Oaks, M. K., Lishan, C., Jianzhong, J., Qian, J., Du, F., Li, N., Xinghai, H., et al. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201423 · Cited by 108
Schneider, H., Valk, E., Leung, R., & Rudd, C. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003842 · Cited by 107
Álvarez-Quiroga, C., Abud‐Mendoza, C., Doníz-Padilla, L., Juárez-Reyes, A., Monsiváis-Urenda, A. E., Baranda, L., & González‐Amaro, R. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9527-5 · Cited by 107
Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy
Bamias, G., Delladetsima, I. K., Perdiki, Μ., Siakavellas, S. I., Goukos, D., Papatheodoridis, G., Daikos, G. L., & Gogas, H. J. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1324032 · Cited by 103
Mead, K. I., Zheng, Y., Manzotti, C. N., Perry, L., Liu, M. K. P., Burke, F., Powner, D., Wakelam, M. J. O., & Sansom, D. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4803 · Cited by 102
Gerold, K. D., Zheng, P., Rainbow, D. B., Zernecke, A., Wicker, L. S., & Kissler, S. (2011) · Diabetes · doi:10.2337/db11-0130 · Cited by 102
Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102
CTLA-4 regulates the requirement for cytokine-induced signals in TH2 lineage commitment
Bour-Jordan, H., Grogan, J. L., Tang, Q., Auger, J., Locksley, R. M., & Bluestone, J. A. (2003) · Nature Immunology · doi:10.1038/ni884 · Cited by 100
Genetic basis of rheumatoid arthritis
Orozco, G., Rueda‐Medina, B., & Martin, J. J. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.09.003 · Cited by 97
Platt, A. M., Gibson, V. B., Patakas, A., Benson, R. A., Nadler, S. G., Brewer, J. M., McInnes, I. B., & Garside, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001311 · Cited by 96
Orban, T., Beam, C. A., Xu, P., Moore, K., Jiang, Q., Deng, J., Müller, S., Gottlieb, P. A., Spain, L. M., Peakman, M., et al. (2014) · Diabetes · doi:10.2337/db14-0047 · Cited by 96
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Yoo, H. Y., Kim, N., Kim, W. S., Lee, S., Kim, S., Kang, S. Y., Jang, H.-Y., Lee, J. E., Kim, J., Kim, S. J., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139253 · Cited by 93
Lovell, D. J., Ruperto, N., Mouy, R., Paz, E. G., Rubio‐Pérez, N., Silva, C. A., Abud‐Mendoza, C., Burgos‐Vargas, R., Gerloni, V., Melo‐Gomes, J. A., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39234 · Cited by 92
Bouqbis, L., Izaabel, H., AKHAYAT, O., Pérez-Lezaun, A., Calafell, F., Bertranpetit, J., & Comas, D. (2003) · Genes and Immunity · doi:10.1038/sj.gene.6363933 · Cited by 91
Ihara, K., Ahmed, S., Nakao, F., Kinukawa, N., Kuromaru, R., Matsuura, N., Iwata, I., Nagafuchi, S., Kohno, H., Miyako, K., et al. (2001) · Immunogenetics · doi:10.1007/s002510100351 · Cited by 90
Expression of CTLA‐4 by Human Monocytes
Wang, X. ‐., Giscombe, R., Yan, Z., Heiden, T., Xu, D., & Lefvert, A. K. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.0300-9475.2001.01019.x · Cited by 90
Personalized treatment of Sézary syndrome by targeting a novel CTLA 4: CD 28 fusion
Sekulić, A., Liang, W. S., Tembe, W., Izatt, T., Kruglyak, S., Kiefer, J., Cuyugan, L., Zismann, V., Legendre, C., Pittelkow, M. R., et al. (2014) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.121 · Cited by 90
Ko, H.-J., Cho, M., Lee, S.-Y., Oh, H., Heo, Y., Moon, Y., Kang, C., Kwok, S., Ju, J. H., Park, S., et al. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.07.006 · Cited by 89
Cutolo, M., Soldano, S., Montagna, P., Sulli, A., SERIOLO, B., Villaggio, B., Triolo, P., Clerico, P., Felli, L., & Brizzolara, R. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2865 · Cited by 86
Araki, M., Chung, D., Liu, S. M., Rainbow, D. B., Chamberlain, G., Garner, V. E. S., Hunter, K. M. D., Vijayakrishnan, L., Peterson, L. B., Oukka, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802610 · Cited by 84
Future biologic targets for IBD: potentials and pitfalls
Melmed, G., & Targan, S. R. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.218 · Cited by 82
CTLA4 is associated with susceptibility to multiple sclerosis
Kantarci, O. H., Hebrink, D. D., Achenbach, S. J., Atkinson, E. J., Waliszewska, A., Buckle, G. J., McMurray, C. T., de Andrade, M., Hafler, D. A., & Weinshenker, B. G. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00395-8 · Cited by 81
Scarsi, M., ZIGLIOLI, T., & Airó, P. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.091176 · Cited by 79
Hurwitz, A. A., Sullivan, T. J., Sobel, R. A., & Allison, J. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042684699 · Cited by 79
Bathon, J. M., Robles, M., Ximenes, A. C., Nayiager, S., Wollenhaupt, J., Durez, P., Gómez-Reino, J. J., Grassi, W., Haraoui, B. P., Shergy, W. J., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.145268 · Cited by 79
Valk, E., Leung, R., Kang, H., Kaneko, K., Rudd, C. E., & Schneider, H. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.024 · Cited by 78
Tyrosine Phosphatase SHP-2 Binding to CTLA-4: Absence of Direct YVKM/YFIP Motif Recognition
Schneider, H., & Rudd, C. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2234 · Cited by 78
Scarsi, M., Paolini, L., Ricotta, D., Pedrini, A., Piantoni, S., Caimi, L., Tincani, A., & Airó, P. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130905 · Cited by 73
Kaine, J., Gladstein, G., Strusberg, I., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200344 · Cited by 73
CD25+CD4+ regulatory T cells exert in vitro suppressive activity independent of CTLA-4
Kataoka, H., Takahashi, S., Takase, K., Yamasaki, S., Yokosuka, T., Koike, T., & Saito, T. (2005) · International Immunology · doi:10.1093/intimm/dxh221 · Cited by 73
Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
Brunner, H. I., Tzaribachev, N., Vega‐Cornejo, G., Louw, I., Berman, A., Penadés, I. C., Antón, J., Ávila‐Zapata, F., Cuttica, R. J., Horneff, G., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40466 · Cited by 73
Walker, E. J., Hirschfield, G. M., Xu, C. D., Lü, Y., Liu, X., Lu, Y., Coltescu, C., Wang, K., Newman, W. G., Bykerk, V. P., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24412 · Cited by 71
Rodríguez, M. R., Núñez‐Roldán, A., Aguilar, F., Valenzuela, A., García, A., & González‐Escribano, M. F. (2002) · Human Immunology · doi:10.1016/s0198-8859(01)00358-5 · Cited by 69
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis
Khoury, S. J., Rochon, J., Ding, L., Byron, M., Ryker, K., Tosta, P., Gao, W., Freedman, M. S., Arnold, D. L., Sayre, P. H., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516662727 · Cited by 68
Bonelli, M. M., Ferner, E., Göschl, L., Blüml, S., Hladik, A., Karonitsch, T., Kiener, H. P., Byrne, R. A., Niederreiter, B., Steiner, C. W., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37787 · Cited by 65
Mochizuki, M., Amemiya, S., Kobayashi, K., Kobayashi, K., Shimura, Y., Ishihara, T., Nakagomi, Y., Onigata, K., Tamai, S., Kasuga, A., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.843 · Cited by 65
Bonelli, M. M., Göschl, L., Blüml, S., Karonitsch, T., Hirahara, K., Ferner, E., Steiner, C.-W., Steiner, G. E., Smolen, J. S., & Scheinecker, C. (2015) · Rheumatology · doi:10.1093/rheumatology/kev403 · Cited by 63
Bostwick, A. D., Salama, A. K. S., & Hanks, B. A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0064-2 · Cited by 60
Cited by
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C.-F., & Wu, T.-C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 395
Advances in immunotherapy for triple-negative breast cancer
Liu, Y., Hu, Y., Xue, J., Li, J., Yi, J., Bu, J., Zhang, Z., Qiu, P., & Gu, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01850-7 · Cited by 337
Metadata
- Authors
- Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 80
- Pages
- 106221
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W3003395886
- Cited by
- 297
- References
- 256
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.